Bipolar I Disorder Clinical Trial
Official title:
Optimizing Response to Li Treatment Through Personalized Evaluation of Individuals With Bipolar I Disorder: The R-LiNK Initiative
Bipolar disorder (BD), especially BD type I, is a highly prevalent mental disorder and a is a highly prevalent mental disorder and an important factor for suicide. Lithium is the key treatment for prevention of BD relapse and has a proven suicide prevention effect. Whilst many cases become asymptomatic with lithium treatment, the majority show sub-optimal response. The objectives of this project are to: - improve outcomes of bipolar I disorder (BDI) cases prescribed lithium through the application of stratified approaches - optimize the early prediction of lithium response using a set of multi-modal biomarkers ("blood omics", Magnetic Resonance Imaging and Li7-Magnetic Resonance Spectroscopy derived-markers) - develop a multidisciplinary multinational network of experts to undertake this and future projects on personalized diagnostics and therapeutics and - implement new, powerful technologies to characterize brain lithium distribution and the blood molecular signature of lithium in responders and non-responders. This cutting edge approach will identify the eligibility criteria for treatment with lithium in BD in terms of response, safety and tolerability.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
| Withdrawn |
NCT01495156 -
Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania
|
Phase 4 | |
| Completed |
NCT00982020 -
Study in Adolescents With Schizophrenia or Bipolar Disorder
|
Phase 4 | |
| Completed |
NCT00746343 -
Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study
|
N/A | |
| Completed |
NCT00177463 -
L-Carnosine for Bipolar I Disorder
|
N/A | |
| Completed |
NCT03257865 -
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder
|
Phase 3 | |
| Completed |
NCT03259555 -
A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
|
Phase 3 | |
| Completed |
NCT04127058 -
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
|
Phase 1 | |
| Recruiting |
NCT05977023 -
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
|
Phase 2 | |
| Recruiting |
NCT05340686 -
Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression
|
N/A | |
| Completed |
NCT03287869 -
A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
|
Phase 3 | |
| Enrolling by invitation |
NCT04987229 -
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT00761761 -
Sensoril(Ashwaganhda)for Bipolar Disorder
|
Phase 3 | |
| Completed |
NCT00232414 -
A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder
|
Phase 3 | |
| Completed |
NCT03292848 -
Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders
|
Phase 1 | |
| Active, not recruiting |
NCT04561622 -
Emotional Proactive Processing in Bipolar Disorder
|
||
| Recruiting |
NCT03943537 -
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
|
Phase 2 | |
| Completed |
NCT03334721 -
Gabapentin for Bipolar & Cannabis Use Disorders
|
Phase 2 | |
| Active, not recruiting |
NCT05658510 -
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
|
Phase 3 | |
| Completed |
NCT00958633 -
Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.
|
Phase 3 |